Literature DB >> 28441702

Pricing in the Market for Anticancer Drugs.

David H Howard1, Peter B Bach2, Ernst R Berndt3, Rena M Conti4.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 28441702     DOI： 10.1257/jep.29.1.139

Source DB:  PubMed          Journal:  J Econ Perspect        ISSN： 0895-3309


× No keyword cloud information.
  85 in total

1.  Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.

Authors:  Stacie B Dusetzina; Nancy L Keating
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

2.  The Value of Considering Cost, and the Cost of Not Considering Value.

Authors:  Leonard B Saltz
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

Review 3.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

4.  Academia and industry: allocating credit for discovery and development of new therapies.

Authors:  Jeffrey S Flier
Journal:  J Clin Invest       Date:  2019-05-20       Impact factor: 14.808

5.  Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.

Authors:  Patricia M Danzon
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

6.  Barriers to conducting cancer trials in Canada: an analysis of key informant interviews.

Authors:  C Bentley; S Sundquist; J Dancey; S Peacock
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

Review 7.  This is a call to oncologists for action.

Authors:  C Micó; A Berrocal; A Blasco; C Caballero; V Iranzo; M Lobo; C Camps
Journal:  Clin Transl Oncol       Date:  2018-05-23       Impact factor: 3.405

8.  Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Authors:  Kathryn R Tringale; Kate T Carroll; Kaveh Zakeri; Assuntina G Sacco; Linda Barnachea; James D Murphy
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

9.  Just how good an investment is the biopharmaceutical sector?

Authors:  Richard T Thakor; Nicholas Anaya; Yuwei Zhang; Christian Vilanilam; Kien Wei Siah; Chi Heem Wong; Andrew W Lo
Journal:  Nat Biotechnol       Date:  2017-12-08       Impact factor: 54.908

10.  Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.

Authors:  Narcyz Ghinea; Miles Little; Wendy Lipworth
Journal:  J Bioeth Inq       Date:  2017-07-18       Impact factor: 1.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.